<DOC>
	<DOCNO>NCT01649570</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial investigate safety efficacy NovoRapidÂ® ( insulin aspart ) meal time insulin subject type 2 diabetes treat basal-bolus regimen Neutral Protamine Hagedorn ( NPH ) human insulin .</brief_summary>
	<brief_title>Safety Efficacy Insulin Aspart Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes Treated insulin least 12 month currently basalbolus regimen least 12 week HbA1c equal 11.0 % BMI ( body mass index ) 30 kg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>